The Exo-srIκB treatment significantly reduced the frequencies of IL-17A- and GM-CSF-producing cells in the PBMCs of RA patients compared to the Exo-Naïve treatment (Fig. 3A). This evidence concerns the gene IL17A and rheumatoid arthritis.